1. Burkhart, C. A., Berman, J. W., Swindell, C. S., and Horwitz, S. B., Relationship between the structure of taxol and other taxanes on induction of tumor necrosis factor-a gene expression and cytotoxicity.Cancer Res., 54, 5779–5782 (1994).
2. Burstein, H. J., Manola, J., Younger, J., Parker, L. M., Bunnell, C. A., Scheib R., Matulonis, U. A., Garber, J. E., Clarke, K. D., Shulman, L. N., and Winer, E. P. Docetaxel administered on a weekly basis for metastatic breast cancer.J. Clin. Oncol., 18, 1212–1219 (2000).
3. Carlson, R. W., Quality of life issues in the treatment of metastatic breast cancer.Oncology, 12, 27–31 (1998).
4. Carmichael, J., Jones, A., and Hutchinson, T., A phase II trial of epirubicin plus paclitaxel in metastatic breast cancer.Semin. Oncol., 24, 44–47 (1997).
5. Chang, A. Y., Boros, L., Asbury, R., Hui, L., and Rubins, J., Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancer.Semin. Oncol., 24, 17–71 (1997).